KALV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
KalVista Pharmaceuticals Inc (KALV) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are neutral, options data shows mixed sentiment, and while analysts are positive with raised price targets, the stock lacks immediate catalysts. Additionally, hedge funds are selling heavily, and financial performance, though improving, still reflects significant losses. Given the user's impatience and unwillingness to wait for optimal entry points, holding off on this stock is recommended.
The MACD is below zero and negatively contracting, indicating bearish momentum. RSI is neutral at 47.832, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 15.378, with resistance at 16.257 and support at 14.499. Overall, technical indicators suggest a neutral trend.
Analyst ratings are consistently positive, with multiple firms raising price targets to $29-$37, citing strong initial performance of Ekterly and its potential as a leading therapy for hereditary angioedema. Gross margin remains high at 91%.
The stock has an 80% chance of declining by -5.29% over the next month based on historical patterns.
In Q3 2025, revenue remained flat at $13.69M YoY, while net income improved by 70.46% YoY but still reflects a significant loss of -$49.48M. EPS improved by 9.52% YoY to -0.92, and gross margin remained strong at 91%.
Analysts are bullish, with multiple firms raising price targets to $29-$37 and maintaining Buy or Outperform ratings. Analysts highlight strong initial performance of Ekterly and its potential market leadership, but they also note the need for sustained demand confirmation in Q1 2026.
